Skip to main content
Clinical Trials/ACTRN12610000813088
ACTRN12610000813088
Completed
Phase 2

A double blinded, randomized, placebo controlled study on the effects of Recombinant Human Erythropoietin on proinflammatory cytokines expression following modified radical mastectomy in females with breast cancer stage II/III

niversity Hospital of Ioannina0 sites22 target enrollmentSeptember 29, 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Female subjects with breast cancer stage II/III undergoing a modified radical mastectomy
Sponsor
niversity Hospital of Ioannina
Enrollment
22
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 29, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
niversity Hospital of Ioannina

Eligibility Criteria

Inclusion Criteria

  • The inclusion criterion was defined as an established preoperative diagnosis of breast cancer stage II or III.

Exclusion Criteria

  • (1\) hemoglobin concentration\>13gr/dl at presentation, (2\) previous history of malignancy, (3\) history of thromboembolic events, (4\) history of seizures, (5\) hypertension, (6\) known allergy to Recombinant Human Erythropoietin , (7\) patients with hepatic, renal, metabolic or endocrine disease, (8\) patients receiving medications known to interfere with wound healing, (9\) neoadjuvant chemotherapy, (11\) recent major surgical procedure or recent history of transfusion and (12\) patient’s denial to informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials